PT945132E - Composicao de ibuprofeno - Google Patents

Composicao de ibuprofeno

Info

Publication number: PT945132E
Authority: PT; Portugal
Prior art keywords: ibupphene; composition
Prior art date: 1998-01-02

Application number

PT99300004T

Other languages

English (en)

Inventor

Frank J Bunick

Feng Lin

Original Assignee

Mcneil Ppc Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-01-02

Filing date

1999-01-04

Publication date

2004-08-31

1999-01-04 Application filed by Mcneil Ppc Inc filed Critical Mcneil Ppc Inc

2004-08-31 Publication of PT945132E publication Critical patent/PT945132E/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nutrition Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Zoology (AREA)
Organic Chemistry (AREA)
Physiology (AREA)
Biophysics (AREA)
Pain & Pain Management (AREA)
Oil, Petroleum & Natural Gas (AREA)
Molecular Biology (AREA)
Rheumatology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

PT99300004T 1998-01-02 1999-01-04 Composicao de ibuprofeno PT945132E (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US244798A	1998-01-02	1998-01-02

Publications (1)

Publication Number	Publication Date
PT945132E true PT945132E (pt)	2004-08-31

Family

ID=21700812

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT99300004T PT945132E (pt)	1998-01-02	1999-01-04	Composicao de ibuprofeno

Country Status (18)

Country	Link
US (3)	US6627214B1 (pt)
EP (1)	EP0945132B1 (pt)
JP (1)	JPH11286441A (pt)
KR (1)	KR19990066891A (pt)
CN (1)	CN1224610B (pt)
AR (1)	AR014230A1 (pt)
AT (1)	ATE265850T1 (pt)
AU (1)	AU9814398A (pt)
BR (1)	BR9805749A (pt)
DE (1)	DE69916922T2 (pt)
DK (1)	DK0945132T3 (pt)
ES (1)	ES2220000T3 (pt)
HU (1)	HUP9803044A3 (pt)
NZ (1)	NZ333474A (pt)
PL (1)	PL198222B1 (pt)
PT (1)	PT945132E (pt)
RU (1)	RU2222323C2 (pt)
ZA (1)	ZA9811959B (pt)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ333474A (en) *	1998-01-02	1999-06-29	Mcneil Ppc Inc	A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat
GB0113843D0 (en) *	2001-06-07	2001-08-01	Boots Co Plc	Therapeutic agents
US6705028B2 (en) *	2001-09-12	2004-03-16	Honda Giken Kogyo Kabushiki Kaisha	Self-propelled snowplow vehicle
DE60100364T2 (de) *	2001-11-20	2003-12-04	Apr Applied Pharma Research S.A., Balerna	Wasserlösliche pharmazeutische Darreichungsform, ausgenommen Brause-Formen, welche nicht-steroidale antientzündliche Wirkstoffe enthält
UY28583A1 (es) *	2003-10-30	2005-05-31	Roche Consumer Health Ag	Forma de presentación del naproxeno sodico
US20070077297A1 (en)	2004-09-30	2007-04-05	Scolr Pharma, Inc.	Modified release ibuprofen dosage form
EP2801354B1 (en)	2004-10-08	2017-02-08	Forward Pharma A/S	Controlled release pharmaceutical compositions comprising a fumaric acid ester
BRPI0709382A2 (pt) *	2006-03-16	2011-07-12	Novartis Ag	forma de dosagem sólida contendo um agente ativo de sabor mascarado
BRPI0718171A2 (pt) *	2006-10-20	2013-11-26	Mcneil Ppc Inc	Combinações de acetaminofeno/ibuprofeno e método para uso das mesmas
US20080113021A1 (en) *	2006-10-25	2008-05-15	Robert Shen	Ibuprofen composition
US7749537B2 (en) *	2006-12-04	2010-07-06	Scolr Pharma, Inc.	Method of forming a tablet
CN101491676B (zh) *	2008-01-22	2012-05-30	沈阳华泰药物研究有限公司	布洛芬组合物
CA2833105C (en) *	2011-04-11	2019-04-23	Ayanda Group As	Oral pharmaceutical dispersion compositions
CN102258490B (zh) *	2011-07-01	2012-10-03	中美天津史克制药有限公司	布洛芬咀嚼片
US9303038B2 (en)	2011-09-06	2016-04-05	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013070586A1 (en)	2011-11-11	2013-05-16	The Wistar Institute Of Anatomy And Biology	Small molecule modulators of prb inactivation
WO2013168021A1 (en)	2012-05-07	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
EP2847169A4 (en)	2012-05-07	2015-09-30	Cellix Bio Private Ltd	COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
US9399634B2 (en)	2012-05-07	2016-07-26	Cellix Bio Private Limited	Compositions and methods for the treatment of depression
WO2013167993A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological degenerative disorders
WO2013168025A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of blood clotting disorders
US9403826B2 (en)	2012-05-08	2016-08-02	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en)	2012-05-08	2016-12-20	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic disorders
WO2013168023A1 (en)	2012-05-08	2013-11-14	Mahesh Kandula	Compositions and methods for treatment of parkinson's disease
WO2013168016A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of metabolic syndrome
US9242939B2 (en)	2012-05-10	2016-01-26	Cellix Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
US9315478B2 (en)	2012-05-10	2016-04-19	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US9394288B2 (en)	2012-05-10	2016-07-19	Cellix Bio Private Limited	Compositions and methods for the treatment of asthma and allergy
WO2013168011A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of chronic pain
WO2013167999A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurologic diseases
US9499526B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of neurologic diseases
WO2013168002A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of neurological conditions
WO2013168004A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of fibromyalgia pain
US9499527B2 (en)	2012-05-10	2016-11-22	Cellix Bio Private Limited	Compositions and methods for the treatment of familial amyloid polyneuropathy
WO2013168001A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2013168005A2 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168000A1 (en)	2012-05-10	2013-11-14	Mahesh Kandula	Compositions and methods for the treatment of severe pain
US9434729B2 (en)	2012-05-23	2016-09-06	Cellix Bio Private Limited	Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
WO2013175376A2 (en)	2012-05-23	2013-11-28	Mahesh Kandula	Compositions and methods for the treatment of local pain
EP2852569B1 (en) *	2012-05-23	2020-10-14	Cellixbio Private Limited	Compositions and methods for the treatment of multiple sclerosis
EP2852570B1 (en)	2012-05-23	2020-04-22	Cellixbio Private Limited	Composition for the treatment of inflammatory bowel disease
CA2873104A1 (en)	2012-05-23	2013-11-28	Cellixbio Private Limited	Compositions and methods for the treatment of mucositis
US9227974B2 (en)	2012-05-23	2016-01-05	Cellex Bio Private Limited	Compositions and methods for the treatment of respiratory disorders
US9108942B1 (en)	2014-11-05	2015-08-18	Mahesh Kandula	Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en)	2012-08-03	2014-02-06	Mahesh Kandula	Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en)	2012-09-06	2014-03-13	Mahesh Kandula	Compositions and methods for the treatment inflammation and lipid disorders
SG11201407325YA (en)	2012-09-08	2014-12-30	Cellix Bio Private Ltd	Compositions and methods for treatment of inflammation and lipid disorders
EP2897646A1 (en) *	2012-09-18	2015-07-29	McNeil-PPC, Inc.	Sustained release oral dosage forms comprising low melting propionic acid derivative particles
AU2013318362A1 (en) *	2012-09-18	2015-03-26	Mcneil-Ppc, Inc.	Suspension pharmaceutical formulations comprising low melting propionic acid derivative particles
WO2014047001A1 (en)	2012-09-18	2014-03-27	Mcneil-Ppc, Inc.	Low melting propionic acid derivative particles for use in oral dosage forms
US9333187B1 (en)	2013-05-15	2016-05-10	Cellix Bio Private Limited	Compositions and methods for the treatment of inflammatory bowel disease
WO2014195961A1 (en)	2013-06-04	2014-12-11	Mahesh Kandula	Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en)	2014-12-31	2015-08-04	Mahesh Kandula	Compositions and methods for the treatment of mucositis
US10010560B2 (en)	2014-02-26	2018-07-03	The Trustees Of The University Of Pennsylvania	Small molecule HSP70 inhibitors
EP3777863A1 (en) *	2014-09-12	2021-02-17	Tobira Therapeutics, Inc.	Cenicriviroc combination therapy for the treatment of fibrosis
WO2016046835A1 (en)	2014-09-26	2016-03-31	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy and neurological disorders
CN107207403A (zh)	2014-09-29	2017-09-26	塞尔利克斯生物私人有限公司	用于治疗多发性硬化的组合物和方法
AU2014414316B2 (en)	2014-10-27	2020-04-09	Cellix Bio Private Limited	Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9150557B1 (en)	2014-11-05	2015-10-06	Cellix Bio Private Limited	Compositions and methods for the treatment of hyperglycemia
US9284287B1 (en)	2014-11-05	2016-03-15	Cellix Bio Private Limited	Compositions and methods for the suppression of carbonic anhydrase activity
US9175008B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Prodrugs of anti-platelet agents
US9321716B1 (en)	2014-11-05	2016-04-26	Cellix Bio Private Limited	Compositions and methods for the treatment of metabolic syndrome
US10208014B2 (en)	2014-11-05	2019-02-19	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological disorders
US9173877B1 (en)	2014-11-05	2015-11-03	Cellix Bio Private Limited	Compositions and methods for the treatment of local pain
US9290486B1 (en)	2014-11-05	2016-03-22	Cellix Bio Private Limited	Compositions and methods for the treatment of epilepsy
US9932294B2 (en)	2014-12-01	2018-04-03	Cellix Bio Private Limited	Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en)	2014-12-17	2015-12-08	Cellix Bio Private Limited	Compositions and methods for the treatment of neurological diseases
JP6679616B2 (ja)	2015-01-06	2020-04-22	セリックスバイオプライヴェートリミテッドＣｅｌｌｉｘＢｉｏＰｒｉｖａｔｅＬｉｍｉｔｅｄ	炎症及び疼痛の治療のための組成物及び方法
US11073521B2 (en)	2015-06-01	2021-07-27	The Wistar Institute Of Anatomy And Biology	Methods for monitoring polymorphonuclear myeloid derived suppressor cells
JP2018529753A (ja)	2015-10-06	2018-10-11	ザ・ウイスター・インステイテユート・オブ・アナトミー・アンド・バイオロジー	転移性及び難治性癌及び腫瘍の処置のための方法及び組成物
GB2581132B (en) *	2019-01-28	2022-06-01	Reckitt Benckiser Health Ltd	Novel composition
US20220176011A1 (en)	2019-02-18	2022-06-09	Lankenau Institute For Medical Research	Scar reducing wound closure materials
DE102020003477A1 (de)	2020-06-10	2021-12-16	DÖHLER GmbH	Pigment für die Weißfärbung von Lebensmitteln, Nahrungsergänzungsmitteln, kosmetischen oder pharmazeutischen Produkten

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1497044A (en)	1974-03-07	1978-01-05	Prodotti Antibiotici Spa	Salts of phenyl-alkanoic acids
US4336244A (en)	1977-09-27	1982-06-22	Colorcon, Inc.	Colored medicinal tablet, natural color pigment and method for using the pigment in coloring food, drug and cosmetic products
DE3440288C2 (de)	1984-11-05	1987-03-12	Gergely, Gerhard, Dr.-Ing., Wien	Pharmazeutische Zubereitung mit einem Gehalt an Ibuprofen sowie Verfahren zu ihrer Herstellung
US4923898A (en) *	1984-12-26	1990-05-08	Analgesic Associates	Analgesic, anti-inflammatory and skeletal muscle relaxant compositions comprising non-steroidal anti-inflammatory drugs and musculoskeletal relaxants and methods of using same
US4874614A (en)	1985-03-25	1989-10-17	Abbott Laboratories	Pharmaceutical tableting method
US4687662A (en)	1985-08-30	1987-08-18	Warner-Lambert Company	Therapeutic effervescent composition
EP0272265B1 (de)	1985-09-25	1991-05-22	Gergely, Gerhard, Dr.	Zerfallstablette und verfahren zu ihrer herstellung
US4753801A (en)	1985-10-25	1988-06-28	Eli Lilly And Company	Sustained release tablets
US4873231A (en) *	1986-04-08	1989-10-10	Smith Walton J	Decreasing the toxicity of an ibuprofen salt
GB8618811D0 (en)	1986-08-01	1986-09-10	Approved Prescription Services	Sustained release ibuprofen formulation
US5519057A (en) *	1986-11-14	1996-05-21	Johnson & Johnson--Merck Pharmaceuticals Co.	Ibuprofen-containing medicament
GB8705083D0 (en)	1987-03-04	1987-04-08	Euro Celtique Sa	Spheroids
US4808413A (en)	1987-04-28	1989-02-28	E. R. Squibb & Sons, Inc.	Pharmaceutical compositions in the form of beadlets and method
US4835187A (en) *	1987-06-15	1989-05-30	American Home Products Corporation	Spray dried ibuprofen
US4851444A (en)	1987-07-10	1989-07-25	Analgesic Associates	Onset-hastened/enhanced analgesia
US5240712A (en)	1987-07-17	1993-08-31	The Boots Company Plc	Therapeutic agents
US4868214A (en)	1987-11-17	1989-09-19	Analgesic Associates	Onset-hastened/enhanced analgesia
CH677606A5 (pt) *	1988-07-12	1991-06-14	Aesculapius Pharma Sa
US4916161A (en) *	1988-10-25	1990-04-10	Bristol-Myers Squibb	Taste-masking pharmaceutical agents
DE3838431A1 (de)	1988-11-12	1990-05-17	Bayer Ag	Ibuprofen-brausezubereitungen
NZ234587A (en) *	1989-08-04	1991-11-26	Mcneil Ppc Inc	A chewable pharmaceutical tablet of compressed coated granules
CA2063141C (en) *	1989-08-04	1997-03-04	Edward J. Roche	Rotogranulations and taste masking coatings for preparation of chewable pharmaceutical tablets
EP0418596A3 (en)	1989-09-21	1991-10-23	American Cyanamid Company	Controlled release pharmaceutical compositions from spherical granules in tabletted oral dosage unit form
US5075291A (en)	1989-11-22	1991-12-24	Ici Americas Inc.	Crystalline sugar alcohol containing uniformly dispersed particulate pharmaceutical compound
IE66933B1 (en) *	1990-01-15	1996-02-07	Elan Corp Plc	Controlled absorption naproxen formulation for once-daily administration
US5175235A (en)	1990-06-04	1992-12-29	Nova Pharmaceutical Corporation	Branched polyanhydrides
IT1246383B (it) *	1990-04-17	1994-11-18	Eurand Int	Metodo per il mascheramento del sapore di farmaci
JPH0426618A (ja)	1990-05-21	1992-01-29	Japan Tobacco Inc	トローチ剤
US5043169A (en)	1990-05-25	1991-08-27	Warner-Lambert Company	Stabilized Sweetner Composition
US5232735A (en)	1990-06-01	1993-08-03	Bioresearch, Inc.	Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers
IT1246350B (it) *	1990-07-11	1994-11-17	Eurand Int	Metodo per ottenere una rapida sospensione in acqua di farmaci insolubili
CA2061520C (en)	1991-03-27	2003-04-22	Lawrence J. Daher	Delivery system for enhanced onset and increased potency
US5464632C1 (en)	1991-07-22	2001-02-20	Prographarm Lab	Rapidly disintegratable multiparticular tablet
ATE238763T1 (de)	1991-11-25	2003-05-15	Richardson Vicks Inc	Verwendung von salicylsäure zur kontrolle von hautfalten und/oder hautatrophie
DE69331839T2 (de)	1992-01-29	2002-12-12	Takeda Chemical Industries, Ltd.	Schnellösliche Tablette und ihre Herstellung
US5429825A (en)	1992-06-26	1995-07-04	Mcneil-Ppc, Inc.	Rotomelt granulation
DE59209706D1 (de)	1992-12-01	1999-07-08	Spirig Ag	S(+)-Ibuprofen enthaltende Arzneimittel
FR2698788B1 (fr)	1992-12-09	1995-03-03	Union Pharma Scient Appl	Composition pharmaceutique effervescente contenant de l'ibuprofène et son procédé de préparation.
DE4303846A1 (de)	1993-02-10	1994-08-11	Merck Patent Gmbh	Verfahren zur Herstellung einer S-Ibuprofen enthaltenden Tablette
IT1264855B1 (it)	1993-06-21	1996-10-17	Zambon Spa	Composizioni farmaceutiche contenenti sali dell'acido s(+)-2-(4-isobutilfenil) propionico con amminoacidi basici
US5576014A (en)	1994-01-31	1996-11-19	Yamanouchi Pharmaceutical Co., Ltd	Intrabuccally dissolving compressed moldings and production process thereof
US5646131A (en) *	1994-02-22	1997-07-08	The Arab Company For Drug Industries And Medical Applicances (Acdima)	Method for solubilizing drugs using cyclodextrins and carboxylic acids
TW442287B (en)	1995-06-13	2001-06-23	American Home Produits Corp	Organoleptically acceptable oral pharmaceutical composition comprising the S(+)1,8-diethyl-1-1,3,4,9-tetrahydropyrano[3,4-b] indole-1-acetic acid (Etodolac)
JPH091997A (ja)	1995-06-21	1997-01-07	Toru Hachisu	折り紙立体額
IE80467B1 (en) *	1995-07-03	1998-07-29	Elan Corp Plc	Controlled release formulations for poorly soluble drugs
US5811131A (en)	1997-02-19	1998-09-22	Mackles; Leonard	Tasteless forms of basic drugs prepared by adsorption in situ
NZ333474A (en) *	1998-01-02	1999-06-29	Mcneil Ppc Inc	A chewable tablet containing ibuprofen, fumaric acid and a non hydrocolloid binder e.g. a wax or a fat

1998
- 1998-12-18 NZ NZ333474A patent/NZ333474A/xx not_active IP Right Cessation
- 1998-12-22 AU AU98143/98A patent/AU9814398A/en not_active Abandoned
- 1998-12-29 JP JP10377466A patent/JPH11286441A/ja active Pending
- 1998-12-30 RU RU98123589/15A patent/RU2222323C2/ru not_active IP Right Cessation
- 1998-12-30 ZA ZA9811959A patent/ZA9811959B/xx unknown
- 1998-12-30 KR KR1019980061469A patent/KR19990066891A/ko not_active Application Discontinuation
- 1998-12-30 AR ARP980106763A patent/AR014230A1/es unknown
- 1998-12-31 BR BR9805749-9A patent/BR9805749A/pt not_active Application Discontinuation
- 1998-12-31 CN CN981267491A patent/CN1224610B/zh not_active Expired - Fee Related
- 1998-12-31 HU HU9803044A patent/HUP9803044A3/hu unknown
- 1998-12-31 PL PL330634A patent/PL198222B1/pl not_active IP Right Cessation
1999
- 1999-01-04 DE DE69916922T patent/DE69916922T2/de not_active Expired - Lifetime
- 1999-01-04 EP EP99300004A patent/EP0945132B1/en not_active Expired - Lifetime
- 1999-01-04 DK DK99300004T patent/DK0945132T3/da active
- 1999-01-04 AT AT99300004T patent/ATE265850T1/de not_active IP Right Cessation
- 1999-01-04 PT PT99300004T patent/PT945132E/pt unknown
- 1999-01-04 ES ES99300004T patent/ES2220000T3/es not_active Expired - Lifetime
- 1999-05-04 US US09/305,027 patent/US6627214B1/en not_active Expired - Lifetime
2003
- 2003-08-05 US US10/635,069 patent/US7078053B2/en not_active Expired - Fee Related
2006
- 2006-06-12 US US11/423,550 patent/US8025897B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US6627214B1 (en)	2003-09-30
HUP9803044A3 (en)	2000-07-28
BR9805749A (pt)	2000-04-11
US20040048924A1 (en)	2004-03-11
CN1224610B (zh)	2012-08-01
AU9814398A (en)	1999-07-22
HU9803044D0 (en)	1999-02-01
ZA9811959B (en)	2000-06-30
AR014230A1 (es)	2001-02-07
US8025897B2 (en)	2011-09-27
EP0945132A3 (en)	1999-12-08
HUP9803044A2 (hu)	1999-09-28
CN1224610A (zh)	1999-08-04
DK0945132T3 (da)	2004-10-04
US20060216349A1 (en)	2006-09-28
DE69916922D1 (de)	2004-06-09
ES2220000T3 (es)	2004-12-01
ATE265850T1 (de)	2004-05-15
DE69916922T2 (de)	2006-11-23
KR19990066891A (ko)	1999-08-16
RU2222323C2 (ru)	2004-01-27
PL330634A1 (en)	1999-07-05
EP0945132A2 (en)	1999-09-29
NZ333474A (en)	1999-06-29
JPH11286441A (ja)	1999-10-19
EP0945132B1 (en)	2004-05-06
PL198222B1 (pl)	2008-06-30
US7078053B2 (en)	2006-07-18

Publication	Publication Date	Title
PT945132E (pt)	2004-08-31	Composicao de ibuprofeno
ID29021A (id)	2001-07-26	Komposisi galantamina pelepasan terkontrol
PT1066027E (pt)	2003-12-31	Composicao farmaceutica de topiramato
ID26186A (id)	2000-12-07	Komposisi sampo
ID28694A (id)	2001-06-28	Komposisi sampo
PT1032542E (pt)	2004-11-30	Composicao de la mineral
ID29430A (id)	2001-08-30	Komposisi herbisida
ID27092A (id)	2001-03-01	Pembuatan ftalat anhidrida
ID26926A (id)	2001-02-22	Komposisi shampo pembentuk mode
ID26549A (id)	2001-01-18	Komposisi-komposisi epotilon
ATE367793T1 (de)	2007-08-15	Schweisshemmende zusammensetzungen
IS2325B (is)	2007-12-15	Örgerðar samsetningar epleróns
DE69926237D1 (de)	2005-08-25	Beschichtungszusammensetzung
DE69919953D1 (de)	2004-10-14	Funktionelle zusammensetzungen
ATE469550T1 (de)	2010-06-15	Antiparasitäre zusammensetzungen
DE69927758D1 (de)	2006-03-02	Imidosilan-Zusammensetzungen
DE69942892D1 (de)	2010-12-09	Gaserzeugende zusammensetzung
DE69928862D1 (de)	2006-01-19	Zusammensetzung
DE69902473D1 (de)	2002-09-12	Kosmetikzusammensetzung
PT1014987E (pt)	2004-06-30	Composicoes orais de levosimendano
DE69919480D1 (de)	2004-09-23	Beschichtungszusammensetzung
ID27889A (id)	2001-05-03	Komposisi-komposisi kopolimer polisiklik
DE69930841D1 (de)	2006-05-24	Deodorantzusammensetzung
TR199903132A3 (tr)	2000-07-21	Metalosan bilesiklerinin aktive edici kompozisyonu.
ID28032A (id)	2001-05-03	TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2